THERAPEUTIC CLASS

Anti-Angiogenics: Their Value in Lung Cancer Therapy

---

Lung cancer is the second most common cancer and the leading cause of cancer-related deaths. Different targeted therapies and the introduction of immunotherapy have successfully improved outcome for patients with non-small lung cancer (NSCLC). Anti-angiogenic drugs are an essential component in the treatment of NSCLC patients. The vascular endothelial growth factor (VEGF)- A antibody bevacizumab is approved for first-line treatment of advanced-stage patients in combination with platinum-based chemotherapy

---

Availability

Detail Information

Series Title

-

Call Number

-

Publisher

: .,

Collation

-

Language

English

ISBN/ISSN

-

Classification

NONE

Content Type

-

Media Type

-

Carrier Type

-

Edition

-

Subject(s)

Oncology
Docetaxel
Carboplatin
Cisplatin
Fonkogem

Specific Detail Info

Oncol Res Treat 2018;41:172–180

Statement of Responsibility

-

Other version/related

File Attachment

Comments

---

You must be logged in to post a comment